Checkpoint Therapeutics (CKPT) Revenue & Revenue Breakdown
Checkpoint Therapeutics Revenue Highlights
Latest Revenue (Y)
$103.00K
Latest Revenue (Q)
$41.00K
Main Segment (Y)
PD-L1 GITR
Main Geography (Y)
PD-L1 GITR
Checkpoint Therapeutics Revenue by Period
Checkpoint Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $103.00K | -46.35% |
| 2022-12-31 | $192.00K | -28.36% |
| 2021-12-31 | $268.00K | -74.93% |
| 2020-12-31 | $1.07M | -37.41% |
| 2019-12-31 | $1.71M | -51.28% |
| 2018-12-31 | $3.51M | 103.25% |
| 2017-12-31 | $1.73M | -32.88% |
| 2016-12-31 | $2.57M | 335.59% |
| 2015-12-31 | $590.00K | - |
Checkpoint Therapeutics generated $103.00K in revenue during NA 2023, up -46.35% compared to the previous quarter, and up 2.94% compared to the same period a year ago.
Checkpoint Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $41.00K | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $6.00K | -80.65% |
| 2023-09-30 | $31.00K | - |
| 2023-06-30 | $31.00K | -11.43% |
| 2023-03-31 | $35.00K | -52.70% |
| 2022-12-31 | $74.00K | 54.17% |
| 2022-09-30 | $48.00K | 166.67% |
| 2022-06-30 | $18.00K | -65.38% |
| 2022-03-31 | $52.00K | 225.00% |
| 2021-12-31 | $16.00K | -44.83% |
| 2021-09-30 | $29.00K | -81.29% |
| 2021-06-30 | $155.00K | 127.94% |
| 2021-03-31 | $68.00K | 151.85% |
| 2020-12-31 | $27.00K | -3.57% |
| 2020-09-30 | $28.00K | -33.33% |
| 2020-06-30 | $42.00K | -95.68% |
| 2020-03-31 | $972.00K | 3788.00% |
| 2019-12-31 | $25.00K | -91.07% |
| 2019-09-30 | $280.00K | -73.36% |
| 2019-06-30 | $1.05M | 198.58% |
| 2019-03-31 | $352.00K | -88.39% |
| 2018-12-31 | $3.03M | 60520.00% |
| 2018-09-30 | $5.00K | -96.06% |
| 2018-06-30 | $127.00K | -62.97% |
| 2018-03-31 | $343.00K | 3.31% |
| 2017-12-31 | $332.00K | -4.87% |
| 2017-09-30 | $349.00K | -0.57% |
| 2017-06-30 | $351.00K | -49.35% |
| 2017-03-31 | $693.00K | 39.16% |
| 2016-12-31 | $498.00K | -8.79% |
| 2016-09-30 | $546.00K | -56.29% |
| 2016-06-30 | $1.25M | 350.90% |
| 2016-03-31 | $277.00K | 326.15% |
| 2015-12-31 | $65.00K | 160.00% |
| 2015-09-30 | $25.00K | - |
Checkpoint Therapeutics generated $41.00K in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up 117.14% compared to the same period a year ago.
Checkpoint Therapeutics Revenue Breakdown
Checkpoint Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|
| PD-L1 GITR | $21.50M | - | - |
| Pd L1 | - | $21.50M | $21.50M |
Checkpoint Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 21: PD-L1 GITR (100.00%).
Checkpoint Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|
| PD-L1 GITR | $21.50M | - | - |
| Pd L1 | - | $21.50M | $21.50M |
Checkpoint Therapeutics's latest annual revenue breakdown by geography, as of Dec 21: PD-L1 GITR (100.00%).
Checkpoint Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| CTMX | CytomX Therapeutics | $101.21M | $25.11M |
| SPRO | Spero Therapeutics | $96.73M | $10.20M |
| FBIO | Fortress Biotech | $59.66M | $13.03M |
| PIRS | Pieris Pharmaceuticals | $42.81M | - |
| ASMB | Assembly Biosciences | $7.16M | $5.79M |
| CUE | Cue Biopharma | $5.49M | $1.72M |
| LUMO | Lumos Pharma | $2.05M | $488.00K |
| CKPT | Checkpoint Therapeutics | $103.00K | $41.00K |
| MBIO | Mustang Bio | - | - |
| RVPH | Reviva Pharmaceuticals | - | - |
| TIL | Instil Bio | - | - |
| ALRN | Aileron Therapeutics | - | - |
| MDNA | Medicenna Therapeutics | - | - |
| NLTX | Neurogene | - | - |
| ACHL | Achilles Therapeutics | - | - |
| ATXI | Avenue Therapeutics | - | - |
| KOD | Kodiak Sciences | - | - |
CKPT Revenue FAQ
What is Checkpoint Therapeutics’s yearly revenue?
Checkpoint Therapeutics's yearly revenue for 2023 was $103K, representing a decrease of -46.35% compared to 2022. The company's yearly revenue for 2022 was $192K, representing a decrease of -28.36% compared to 2021. CKPT's yearly revenue for 2021 was $268K, representing a decrease of -74.93% compared to 2020.
What is Checkpoint Therapeutics’s quarterly revenue?
Checkpoint Therapeutics's quarterly revenue for Q2 2024 was $41K, a 100.00% increase from the previous quarter (Q1 2024), and a 32.26% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a -100.00% decrease year-over-year (Q1 2023). CKPT's quarterly revenue for Q4 2023 was $6K, a -80.65% decrease from the previous quarter (Q3 2023), and a -91.89% decrease year-over-year (Q4 2022).
What is Checkpoint Therapeutics’s revenue growth rate?
Checkpoint Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -61.57%, and for the last 5 years (2019-2023) was -93.97%.
What are Checkpoint Therapeutics’s revenue streams?
Checkpoint Therapeutics's revenue streams in c 21 are PD-L1 GITR
What is Checkpoint Therapeutics’s main source of revenue?
For the fiscal year ending Dec 21, the largest source of revenue of Checkpoint Therapeutics was PD-L1 GITR. This segment made a revenue of $21.5M, representing 100.00% of the company's total revenue.